United Therapeutics Gestione
Gestione criteri di controllo 2/4
United Therapeutics Il CEO è Martine Rothblatt, nominato in Jan1996, e ha un mandato di 28.83 anni. la retribuzione annua totale è $ 16.96M, composta da 8.7% di stipendio e 91.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.44% delle azioni della società, per un valore di $ 241.05M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 15.6 anni e 22.2 anni.
Informazioni chiave
Martine Rothblatt
Amministratore delegato
US$17.0m
Compenso totale
| Percentuale dello stipendio del CEO | 8.7% |
| Mandato del CEO | 28.8yrs |
| Proprietà del CEO | 1.4% |
| Durata media del management | 15.6yrs |
| Durata media del Consiglio di amministrazione | 22.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Compensazione vs Mercato: La retribuzione totale di Martine ($USD 16.96M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 12.87M ).
Compensazione vs guadagni: La retribuzione di Martine è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Martine Rothblatt (69 yo)
28.8yrs
Mandato
US$16,958,057
Compensazione
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.44% $ 241.1m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 963.5k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.017% $ 2.8m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.7m | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Associate Vice President of Human Resources | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Strategic Operations & Logistics | no data | Nessun dato | Nessun dato | |
| Executive VP of Technical Operations | 15.6yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Product Development & Xenotransplantation | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Medical Officer | no data | Nessun dato | Nessun dato |
15.6yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di UTHR è esperto e expertise (durata media dell'incarico 15.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.44% $ 241.1m | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.5m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.9m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 654.6k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 748.1k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0094% $ 1.6m | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.4m | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 9.4yrs | US$488.66k | 0.017% $ 2.8m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.5m |
22.2yrs
Durata media
76yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di UTHR è composto da personale esperto e esperto (durata media dell'incarico 22.2 anni).